Clinical trial Recruiting at 3 sites Phase 1 Interventional Ages 18 and up

Higher radiation doses for treating recurrent ventricular tachycardia

Official title: Dose Escalation for Stereotactic Cardiac Radiation Therapy of Recurrent Ventricular Tachyarrhythmia - a Multi Center, Phase II Clinical Trial

Run by University of Zurich · NCT05594368 · Data updated 2026-11-12

This study is testing if higher doses of targeted radiation can help people with recurrent ventricular tachycardia who haven't had success with other treatments.

Quick facts

PhasePhase 1
Study typeInterventional
Ages18 Years and up
SexAll
Enrollment15 (estimated)
SponsorUniversity of Zurich
Academic / other
Drugs / interventionsradiation
Locations3 sites (Ostrava and 2 other locations)
StatusRecruiting
StartedJuly 1, 2022
Main results expectedDecember 31, 2027
Study endsDecember 31, 2028
Registry record updatedAugust 21, 2026
Trial IDNCT05594368 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Ideal candidates are adults with structural heart disease and a history of recurrent VT despite previous ablation attempts.

Probably not a fit

Patients with only premature ventricular contractions or those with reversible causes of VT may not benefit from this study.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This clinical trial aims to evaluate the effectiveness of dose-escalated stereotactic arrhythmia radioablation in patients with recurrent ventricular tachycardia (VT). The study hypothesizes that higher radiation doses will promote transmural scar formation, which is believed to be crucial for reducing long-term VT recurrence rates. Participants will include those with structural heart disease who have previously failed catheter ablation attempts. The trial will assess the safety and efficacy of this approach compared to the standard single dose of 25 Gy.

Why it matters

Potential benefit: If successful, this approach could significantly lower the recurrence rate of ventricular tachycardia in patients who have not responded to traditional treatments.

How similar studies have gone: While this approach is innovative, similar studies have not been widely reported, indicating a novel exploration in the treatment of recurrent VT.

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion Criteria:

Patients with structural heart disease, in particular ischemic and non-ischemic cardiomyopathy: Implanted ICD and/or CRT-D. Prior ≥1 failed catheter ablation (with endocardial ± epicardial approach based on the substrate location and the ECG morphology of clinical VTs) procedure to control sustained monomorphic VT using currently recommended mapping and ablation techniques,2 or patients in whom ablation is not feasible. Reasons for lack of epicardial ablation and non-feasibility of catheter ablation must be specified. Sustained VT recurrence after catheter ablation on optimised antiarrhythmic medication.

Age ≥18 years. IRB-approved, written informed consent must be provided

Exclusion Criteria:

Patients with only premature ventricular contractions.

Patients with sustained VT/VF who demonstrate:

Acute myocardial infarction; Primary electrical disease (channelopathy); Reversible and treatable cause (e.g., drug-induced or intoxication) of VT that can be adequately addressed otherwise; A target that cannot be safely and precisely defined based on stereotactic radiotherapy accuracy requirements (e.g., anatomical interference from OARs, overlapping prior radiation therapy to the thoracic region); Pregnancy or breastfeeding; Inability to provide informed consent.

Where it's running

  • University Hospital Ostrava
    Ostrava, Czechia
    Recruiting
  • University Hospital Zurich
    Zurich, Canton of Zurich, Switzerland
    Recruiting
  • Inselspital Bern
    Bern, Switzerland
    Recruiting

Study contacts

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.